Celltrion, Inc. (068270.KS)
KRW 193100.0
(-3.06%)
KRW 193100.0
(-3.06%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 535.64 Billion KRW | -0.41% |
| 2022 | 537.83 Billion KRW | -7.18% |
| 2021 | 579.46 Billion KRW | 11.92% |
| 2020 | 517.75 Billion KRW | 72.0% |
| 2019 | 301.03 Billion KRW | 22.49% |
| 2018 | 245.75 Billion KRW | -33.26% |
| 2017 | 368.22 Billion KRW | 106.87% |
| 2016 | 177.99 Billion KRW | 15.51% |
| 2015 | 154.08 Billion KRW | 36.75% |
| 2014 | 112.67 Billion KRW | 9.98% |
| 2013 | 102.45 Billion KRW | -41.26% |
| 2012 | 174.43 Billion KRW | 3.95% |
| 2011 | 167.8 Billion KRW | 54.84% |
| 2010 | 108.37 Billion KRW | 85.11% |
| 2009 | 58.54 Billion KRW | 301.79% |
| 2008 | 14.57 Billion KRW | 536.89% |
| 2007 | 2.28 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 78.01 Billion KRW | 247.67% |
| 2024 Q1 | 22.43 Billion KRW | 2029.08% |
| 2023 FY | 535.64 Billion KRW | -0.41% |
| 2023 Q4 | 1.05 Billion KRW | -99.52% |
| 2023 Q1 | 165.26 Billion KRW | 138.81% |
| 2023 Q3 | 221.82 Billion KRW | 50.38% |
| 2023 Q2 | 147.5 Billion KRW | -10.74% |
| 2022 Q4 | 69.2 Billion KRW | -58.49% |
| 2022 Q3 | 166.69 Billion KRW | -9.12% |
| 2022 Q2 | 183.41 Billion KRW | 54.75% |
| 2022 Q1 | 118.52 Billion KRW | -5.06% |
| 2022 FY | 537.83 Billion KRW | -7.18% |
| 2021 Q3 | 136.27 Billion KRW | 7.91% |
| 2021 Q1 | 195.65 Billion KRW | 88.05% |
| 2021 Q2 | 126.28 Billion KRW | -35.46% |
| 2021 FY | 579.46 Billion KRW | 11.92% |
| 2021 Q4 | 124.84 Billion KRW | -8.39% |
| 2020 Q4 | 104.04 Billion KRW | -39.05% |
| 2020 FY | 517.75 Billion KRW | 72.0% |
| 2020 Q1 | 104.93 Billion KRW | 6.57% |
| 2020 Q3 | 170.68 Billion KRW | 23.6% |
| 2020 Q2 | 138.09 Billion KRW | 31.59% |
| 2019 Q1 | 63.92 Billion KRW | 129.32% |
| 2019 FY | 301.03 Billion KRW | 22.49% |
| 2019 Q3 | 61.43 Billion KRW | -20.43% |
| 2019 Q4 | 98.46 Billion KRW | 60.28% |
| 2019 Q2 | 77.2 Billion KRW | 20.77% |
| 2018 Q3 | 56.17 Billion KRW | -30.23% |
| 2018 Q4 | 27.87 Billion KRW | -50.37% |
| 2018 FY | 245.75 Billion KRW | -33.26% |
| 2018 Q1 | 81.2 Billion KRW | 9.56% |
| 2018 Q2 | 80.5 Billion KRW | -0.86% |
| 2017 Q2 | 114.16 Billion KRW | 68.45% |
| 2017 FY | 368.22 Billion KRW | 106.87% |
| 2017 Q4 | 74.11 Billion KRW | -27.99% |
| 2017 Q3 | 102.92 Billion KRW | -9.84% |
| 2017 Q1 | 67.76 Billion KRW | 36.49% |
| 2016 Q4 | 49.65 Billion KRW | -14.58% |
| 2016 Q3 | 58.13 Billion KRW | -1.97% |
| 2016 Q1 | 10.91 Billion KRW | -77.43% |
| 2016 FY | 177.99 Billion KRW | 15.51% |
| 2016 Q2 | 59.29 Billion KRW | 443.3% |
| 2015 Q1 | -14.6 Billion KRW | -225.26% |
| 2015 Q3 | 62.44 Billion KRW | 7.88% |
| 2015 Q4 | 48.35 Billion KRW | -22.56% |
| 2015 Q2 | 57.88 Billion KRW | 496.46% |
| 2015 FY | 154.08 Billion KRW | 36.75% |
| 2014 Q2 | 71.82 Billion KRW | 413.33% |
| 2014 FY | 112.67 Billion KRW | 9.98% |
| 2014 Q4 | 11.65 Billion KRW | -23.32% |
| 2014 Q3 | 15.2 Billion KRW | -78.84% |
| 2014 Q1 | 13.99 Billion KRW | 509.66% |
| 2013 Q3 | 36.58 Billion KRW | 2.06% |
| 2013 FY | 102.45 Billion KRW | -41.26% |
| 2013 Q4 | -3.41 Billion KRW | -109.34% |
| 2013 Q1 | 33.44 Billion KRW | -36.63% |
| 2013 Q2 | 35.84 Billion KRW | 7.19% |
| 2012 FY | 174.43 Billion KRW | 3.95% |
| 2012 Q1 | 41.54 Billion KRW | 0.0% |
| 2012 Q3 | 37.73 Billion KRW | -3.23% |
| 2012 Q4 | 52.77 Billion KRW | 39.85% |
| 2012 Q2 | 38.99 Billion KRW | -6.15% |
| 2011 Q3 | 41.95 Billion KRW | 1.02% |
| 2011 Q2 | 41.52 Billion KRW | 3.62% |
| 2011 Q1 | 40.07 Billion KRW | 32.33% |
| 2011 FY | 167.8 Billion KRW | 54.84% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q2 | 29.07 Billion KRW | 58.2% |
| 2010 Q1 | 18.37 Billion KRW | 2.76% |
| 2010 Q3 | 30.64 Billion KRW | 5.4% |
| 2010 Q4 | 30.28 Billion KRW | -1.16% |
| 2010 FY | 108.37 Billion KRW | 85.11% |
| 2009 Q4 | 17.88 Billion KRW | 43.42% |
| 2009 FY | 58.54 Billion KRW | 301.79% |
| 2009 Q3 | 12.46 Billion KRW | -24.45% |
| 2009 Q2 | 16.5 Billion KRW | 41.2% |
| 2009 Q1 | 11.68 Billion KRW | 7575.23% |
| 2008 Q1 | 178.18 Million KRW | 0.0% |
| 2008 Q3 | 12.77 Billion KRW | 836.97% |
| 2008 Q4 | 152.28 Million KRW | -98.81% |
| 2008 FY | 14.57 Billion KRW | 536.89% |
| 2008 Q2 | -1.73 Billion KRW | -1072.85% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q2 | 447.8 Million KRW | -29.34% |
| 2007 Q1 | 633.76 Million KRW | 0.0% |
| 2007 FY | 2.28 Billion KRW | 0.0% |
| 2007 Q3 | 750.55 Million KRW | 67.61% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ORIENT BIO Inc. | 12.87 Billion KRW | -4061.648% |
| Green Cross Holdings Corporation | -54.13 Billion KRW | 1089.443% |
| Green Cross Holdings Corporation | -26.63 Billion KRW | 2111.311% |
| Pharmicell Co., Ltd. | 3.57 Billion KRW | -14870.666% |
| Green Cross Corporation | -26.63 Billion KRW | 2111.311% |
| GeneOne Life Science, Inc. | -77.76 Billion KRW | 788.776% |
| Samsung Biologics Co.,Ltd. | 857.69 Billion KRW | 37.548% |
| SK bioscience Co.,Ltd. | 22.31 Billion KRW | -2300.102% |
| SK Biopharmaceuticals Co., Ltd. | -32.88 Billion KRW | 1728.958% |
| Prestige BioPharma Limited | -32.92 Billion KRW | 1727.059% |